Abstract: Said invention refers to a pharmaceutical form for selective colon delivery of drugs or bioactive molecules degraded and/or poorly absorbed in the gastrointestinal tract. The system comprises a core consisting of the active ingredient, and a protease inhibitor layer and/or an absorption enhancer layer, said core being separated from these layers by means of a polymer that swells and/or dissolves and/or is degraded when in contact with the biological fluids present in the gastro-intestinal tract; depending on the thickness of the polymeric layer, the release of the drug can be modulated with respect to the inhibitor and/or promoter.

Abstract: The present invention refers to an oral dosage form intended for the time-controlled release of drugs comprising a container for one or more active ingredients optionally in admixture with pharmaceutically acceptable excipients, said container consisting of at least two parts or elements that can be joined together so as to seal the contents, at least one of said elements being composed of one or more hydrophilic polymers that undergo a decrease in the glassy-rubbery transition temperature when in contact with aqueous fluids, except for polymers with pH dependent solubility soluble only at pH values above 5, optionally in admixture with pharmaceutically acceptable excipients, the wall of the elements of the container being of such thickness as to delay the release of the contained drug with respect to the time of administration.

Abstract: A time-specific delayed/pulsatile release dosage form which comprises: a core comprising at least one active principle and at least one disintegrating agent; a sealing layer surrounding the core essentially consisting of one or more water soluble or water insoluble pH independent polymers; an outer coating essentially consisting of one or more hydrophilic pH independent polymers; wherein: the at least one disintegrating agent is present in amounts of 1-20% by weight and the at least one active principle is present in amounts of 1-80% by weight, with respect to the core; the sealing layer accounts for 0.1-10% by weight, with respect to the core; the outer coating accounts for 5-500% by weight, with respect to the core. These coated cores are capable of ensuring the immediate release of the active principle after a pre-defined lag time, independently of physiological pH variations occurring in the gastro-intestinal tract of mammals.